Picture three retinal structures — the choroid, the retinal pigment epithelium sitting just above it, and the photoreceptors resting on top of that — wasting away in lockstep rather than one at a time. That’s choroideremia, and because the responsible gene sits on the X chromosome, the condition turns up almost exclusively among boys and men; women carrying the gene usually get by with only subtle changes that rarely interfere with everyday sight.
For families arriving from Rwanda, the path to this diagnosis often begins with a routine fundus photograph on a male relative that a local eye doctor recognised as different from the usual RP pattern — different enough to warrant a genetic test confirming choroideremia specifically, rather than settling for a broader retinal-dystrophy label.

Associate Professor, Vitreo-Retina Surgeon. 10+ Years Experience

Senior Consultant Ophthalmologist & Eye Surgeon· 26+ yrs experience

Consultant Ophthalmologist & Eye Surgeon, MD, DO .16+ Years Experience
With central vision holding on for so long in most cases, treatment is built around protecting that window for as long as possible — weighing regenerative stem cell therapy for suitable candidates, alongside regular monitoring of disease progression and early planning for low-vision support ahead of any eventual changes centrally.
It’s simply how X-linked inheritance works. Men have a single X chromosome, so one faulty CHM copy is all it takes to cause the disease. Women have two, and the working copy carriers still have is generally enough to spare them meaningful vision loss.
No — the odds work out to roughly one in two for each son to inherit the mutation, and roughly one in two for each daughter to become a carrier. A genetic test can put a firmer number on that for your own family.
Frequently, yes. The scalloped thinning across both the choroid and RPE gives choroideremia a somewhat different look on examination than the more even photoreceptor loss typical of RP, though a genetic test is still what confirms it beyond doubt.
The sooner the better, generally, since it leaves the most options open while central vision remains sharp. We’d much rather assess a patient well before central-vision symptoms appear than after.
